Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.
Ping-Ching HsuSusan A KadlubarEric Robb SiegelLora J RogersValentina K TodorovaL Joseph SuIssam MakhoulPublished in: PloS one (2020)
ClinicalTrials.gov Identifier: NCT00203502.